European Pharmaceutical Review

AUGUST 14, 2023

The US Food and Drug Administration (FDA) has approved Janssen’s Akeega (niraparib and abiraterone acetate), for the treatment of adult patients BRCA-positive metastatic castration-resistant prostate cancer (mCRPC). The FDA approval was based on positive results from the multi-centre Phase III MAGNITUDE study.

FDA 52

FDA Food and Drug Administration Medicine Prospecting 52

Pharma Leaders

MAY 18, 2023

The US Food and Drug Administration (FDA) has accepted Ardelyx’s resubmitted New Drug Application (NDA) for XPHOZAH (tenapanor) to control serum phosphate in adult patients with chronic kidney disease on dialysis who have had an insufficient response or intolerance to a phosphate binder therapy.

Food and Drug Administration 52

Food and Drug Administration FDA Side effects Prospecting 52

PM360

SEPTEMBER 21, 2023

The recent wave of Alzheimer’s Disease (AD) drug approvals and promising pivotal trial data from various drug manufacturers has been celebrated by physicians, patients, caregivers, and advocacy groups across the U.S. When used in CMS-approved prospective comparative studies, the data for which may be collected in a registry.

Manufacturing 99

Manufacturing FDA Recruitment Prospecting 99

Pharmaceutical Technology

MAY 9, 2023

Revenue prospects for Novo Nordisk’s blockbuster diabetes and weight-loss drug semaglutide in Brazil have been dealt a major blow after a federal court denied a request by the Danish firm for two patent extensions. Back in Brazil, however, the denial of semaglutide patent extensions is a loss for Lilly, too.

Marketing 59

Marketing Manufacturing Prospecting Physicians 59

Contrarian Sales Techniques

DECEMBER 14, 2022

In 2021, the demand for physician-administered drugs decreased due to the outbreak. Bright Prospects Indicates by Zacks Industry Rank The large-cap pharmaceutical industry, which is a part of the Medical sector, has a favorable Industry rank of A. The US Food and Drug Administration (FDA) has approved Wegovy, which is a 2.4-mg

Food and Drug Administration 52

Food and Drug Administration Pharmaceutical Sales Medicine 52

Legacy MEDSearch

MAY 1, 2023

The results were featured in the late-breaking session ( LBA01-05 ) at the American Urological Association (AUA) 2023 Annual Meeting in Chicago on Sunday, April 30 th. Results from the trial are under review by the FDA. We continue to work with the FDA and look forward to introducing this innovative solution to physicians and patients.”

Patients 52

Patients Medical Safety Recruitment 52

Evolve Your Success

APRIL 11, 2023

My partner is an emergency medicine physician. We have launched into the US marketplace and got the product design through FDA. Those revisits that healthcare facilities and physicians have are not covered. Sometimes they go back to the primary care physician to do it. You can do that up to five times.

Sales 52

Sales Medical Medical sales Media 52